<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966120</url>
  </required_header>
  <id_info>
    <org_study_id>ALA-AK-CT007</org_study_id>
    <secondary_id>2013-002510-12</secondary_id>
    <nct_id>NCT01966120</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis With Photodynamic Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED® Lamp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofrontera Bioscience GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biofrontera Bioscience GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz)
      versus placebo in the field-directed treatment of mild to moderate actinic keratosis with
      photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patient complete response</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete responder rate at week 12 after last PDT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and secondary efficacy parameters</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subject assessment of pain during PDT, lesion complete response, histopathological confirmed response rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>BF-200 ALA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photodynamic therapy with BF-200 ALA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BF-200 ALA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Photodynamic therapy with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy</intervention_name>
    <arm_group_label>BF-200 ALA</arm_group_label>
    <arm_group_label>Placebo to BF-200 ALA</arm_group_label>
    <other_name>PDT</other_name>
    <other_name>BF-RhodoLED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 85 years of age (inclusive)

          -  Presence of 4 to 8 clinically confirmed AK target lesions of mild to moderate
             intensity within 1-2 fields

        Exclusion Criteria:

          -  History of hypersensitivity to 5-ALA or any ingredient of BF-200 ALA

          -  Current treatment with immunosuppressive therapy

          -  Presence of other malignant or benign tumors of the skin within the treatment area
             (eg malignant melanoma, basal cell carcinoma [BCC] or squamous cell carcinoma [SCC])
             within the last 4 weeks

          -  Confirmed diagnosis of SCC for the representative lesion by screening biopsy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Reinhold, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologisches Zentrum Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>Field-directed Treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
